SBIR/STTR Research Award

A nanoparticle delivery system for CRISPR/Cas9 based therapeutics

Award identifier b47cf2a7c0c2731869533e20de7e592a5aa2c78c4ca9aeb670e07caedd7297daAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,482,545

Program and phase

STTR · Phase II

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ATGC Inc.
Proposal award date
2018-09-01
Contract end date
2020-08-31
UEI
F3KRQG95DCF6
Solicitation number
PA14-308
Topic code
100

Research abstract

Abstract Applications of customizable nucleases such as CRISPRclustered regularly interspaced short palindromic repeatsCasCRISPR associated proteinhave enabled efficient and precise gene correction in vitroand hold promises for eventually achieving in vivo gene correction therapyHoweverto apply CRISPR Casin therapeutic settingsseveral major challenges remain to be addressedihomologous recombinationHReven with the help of Casis still of low efficiencyiiCasis associated with off target effectsandiiithere is a lack of an efficient virus free system to deliver CRISPR Caselements in vivoThe present proposal focuses on the challenge of lack of an efficient non viral in vivo delivery systemWe recently developed novel hyperbranched polymersHPswith high nucleic acid binding affinitynegligible cytotoxicityand achieved satisfactory delivery of microRNAs both in vitro and in vivoHere we propose to develop hyperbranched HPbased system for effective delivery of Casplasmid DNApDNAIn Phase Iwe will work to formulate and test new HPs for effectively packaging of CaspDNAand evaluate the safety and efficacy of these HPs in vitroIn Phase IIwe will expand the capability of HPs for Casin vivoand apply HPs for Castherapeutics in animal modelsSuccess of the proposed work will have significant impacts on basic and translational research and accelerate the development of Castherapeutics Project Narrative One major challenge for CRISPRclustered regularly interspaced short palindromic repeatsCasCRISPR associated proteintherapeutics is the lack of an efficient non viral in vivo delivery systemThe present work aims to develop a nanopolymer platform for delivery of Casplasmid DNA both in vitro and in vivoSuccess of the proposed work will have significant impacts on basic and translational researchand accelerate the development of Castherapeutics

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

7 SBIR/STTR records share this UEI (2017–2023). Reported award amounts total $4,801,284. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.